Core Viewpoint - The stock of Shangrong Medical (002551) has shown a slight increase in price, but the company is facing significant financial challenges, including declining revenues and profits [1][3]. Financial Performance - As of October 23, 2025, Shangrong Medical's stock closed at 4.15 yuan, with a 0.48% increase and a trading volume of 150,100 shares, amounting to a total transaction value of 61.96 million yuan [1]. - The company's main revenue for the first half of 2025 was 528 million yuan, a year-on-year decrease of 16.38%, and the net profit attributable to shareholders was -7.76 million yuan, down 155.31% year-on-year [3]. - In Q2 2025, the company reported a single-quarter revenue of 248 million yuan, a decline of 30.12%, and a net profit of -21.72 million yuan, a staggering drop of 15,273.62% year-on-year [3]. Market Position and Ratios - Shangrong Medical's total market capitalization is 3.509 billion yuan, significantly lower than the industry average of 11.613 billion yuan, ranking 97th out of 124 in the medical device industry [3]. - The company has a negative price-to-earnings ratio of -226.13 and a net profit margin of -0.86%, indicating poor profitability compared to the industry average [3]. - The gross margin stands at 16.47%, which is substantially below the industry average of 51.39%, ranking 119th out of 124 [3]. Capital Flow Analysis - On October 23, 2025, the net inflow of main funds was 5.51 million yuan, accounting for 8.9% of the total transaction value, while retail investors experienced a net outflow of 2.03 million yuan, representing 3.28% of the total [1][2]. - Over the past five days, the stock has seen fluctuating capital flows, with notable net outflows from retail investors on several days, indicating a lack of confidence among smaller investors [2].

Core Viewpoint - The company, Shangrong Medical, has successfully returned 150 million RMB of temporarily used funds to its fundraising account, ensuring compliance with regulations and maintaining the integrity of its fundraising purposes [1][2]. Trading Information Summary - On October 22, 2025, Shangrong Medical's stock closed at 4.13 RMB, with an increase of 0.73% and a turnover rate of 3.83%. The trading volume was 234,100 shares, resulting in a transaction amount of 96.37 million RMB [1]. - On the same day, the main funds experienced a net outflow of 15.26 million RMB, while retail investors saw a net inflow of 13.30 million RMB [2]. Company Announcement Summary - On January 10, 2025, the company held a board meeting where it approved the temporary use of up to 150 million RMB from the proceeds of a public convertible bond issuance to supplement working capital for a period not exceeding twelve months [1]. - As of October 21, 2025, the company has fully returned the 150 million RMB to the fundraising account, and the return was in accordance with relevant regulations [1][2].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002551 证券简称：尚荣医疗 公告编号：2025-049 深圳市尚荣医疗股份有限公司关于归还用于 特此公告。 深圳市尚荣医疗股份有限公司（以下简称"公司"）于2025年1月10日召开第八届董事会第五次临时会议 审议通过了《关于公司使用部分闲置募集资金暂时补充流动资金的议案》。同意公司使用不超过人民币 15,000万元的公开发行可转换公司债券部分闲置募集资金暂时补充流动资金，使用期限自董事会审议通 过之日起不超过十二个月。具体内容详见公司指定信息披露报刊《中国证券报》、《证券时报》、《证 券日报》和《上海证券报》及指定信息披露网站巨潮资讯网 （www.cninfo.com.cn）上披露的《深圳市 尚荣医疗股份有限公司关于使用部分闲置募集资金暂时补充流动资金的公告》（公告编号：2025- 006）。 根据上述决议，公司合计从募集资金账户中共划出人民币15,000万元闲置募集资金暂时补充流动资金， 公司在使用闲置募集资金暂时补充流动资金期间，对资金进行了合理的安排与使用，没有影响募集资金 投资计划的正常进行，没有变相改变募集资金用途，资金运用情况良好。 ...

截至2025年10月21日收盘，尚荣医疗(002551)报收于4.1元，上涨1.99%，换手率2.5%，成交量15.3万 手，成交额6229.27万元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：10月21日主力资金净流入379.79万元，显示主力对个股短期态度偏积极。 来自公司公告汇总：尚荣医疗已全额归还此前用于暂时补充流动资金的1.5亿元募集资金，合规履 行相关程序。 交易信息汇总资金流向 10月21日主力资金净流入379.79万元；游资资金净流出473.56万元；散户资金净流入93.77万元。 公司公告汇总关于归还用于暂时补充流动资金的闲置募集资金的公告 深圳市尚荣医疗股份有限公司于2025年1月10日召开第八届董事会第五次临时会议，审议通过使用不超 过人民币15,000万元的公开发行可转换公司债券部分闲置募集资金暂时补充流动资金，使用期限自董事 会审议通过之日起不超过十二个月。公司合计从募集资金账户划出15,000万元用于暂时补充流动资金， 期间资金使用合理，未影响募集资金投资计划，未变相改变募集资金 ...

Core Points - The stock of Shangrong Medical (002551) closed at 4.1 yuan on October 21, 2025, with a 1.99% increase from the previous trading day, resulting in a total market capitalization of 3.467 billion yuan [1] - The company announced a temporary use of idle raised funds amounting to 150 million yuan for supplementing working capital, which was approved during the fifth temporary meeting of the eighth board of directors on January 10, 2025 [1] - The funds were drawn from the fundraising account and have been fully returned to the account as of October 21, 2025, complying with relevant regulations [1] Financial Performance - On the trading day, the stock opened at 4.02 yuan, reached a high of 4.11 yuan, and a low of 3.99 yuan, with a trading volume of 62.2927 million yuan and a turnover rate of 2.5% [1] Fund Management - The company utilized the 150 million yuan for temporary working capital without affecting the investment plans of the raised funds or changing their intended use [1] - The return of the funds was communicated to the sponsoring institution and the representative of the sponsor [1]

公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：002551 证券简称：尚荣医疗 公告编号：2025-049 深圳市尚荣医疗股份有限公司 关于归还用于暂时补充流动资金的闲置募集资金的 截至 2025 年 10 月 21 日，公司已将上述用于暂时补充流动资金的募集资金 人民币 15,000 万元全部归还至公司募集资金账户，使用期限未超过 12 个月。截 至本公告披露日，公司用于暂时补充流动资金的募集资金已全部归还完毕，同时， 已将上述募集资金的归还情况通知了公司的保荐机构及保荐代表人。 特此公告。 深圳市尚荣医疗股份有限公司 董 事 会 2025 年 10 月 22 日 深圳市尚荣医疗股份有限公司（以下简称"公司"）于2025年1月10日召开 第八届董事会第五次临时会议审议通过了《关于公司使用部分闲置募集资金暂时 补充流动资金的议案》。同意公司使用不超过人民币15,000万元的公开发行可转 换公司债券部分闲置募集资金暂时补充流动资金，使用期限自董事会审议通过之 日起不超过十二个月。具体内容详见公司指定信息披露报刊《中国证券报》、《证 券时报》、《 ...

Core Insights - The stock of Shangrong Medical (002551) closed at 4.02 yuan on October 20, 2025, with a 2.03% increase and a trading volume of 120,600 shares, amounting to a total transaction value of 48.18 million yuan [1] Financial Performance - Shangrong Medical reported a main revenue of 528 million yuan for the first half of 2025, a year-on-year decrease of 16.38% [2] - The net profit attributable to shareholders was -7.76 million yuan, down 155.31% year-on-year [2] - The company's second-quarter revenue was 248 million yuan, reflecting a 30.12% decline compared to the same quarter last year [2] - The net profit for the second quarter was -21.72 million yuan, a staggering decrease of 15,273.62% year-on-year [2] - The company’s gross margin stood at 16.47%, significantly lower than the industry average of 51.83% [2] Market Position - Shangrong Medical's total market capitalization is 3.399 billion yuan, ranking 97th in the medical device industry [2] - The company has a net asset value of 2.763 billion yuan, ranking 57th in the industry [2] - The price-to-earnings ratio (P/E) is -219.05, indicating negative earnings, while the industry average is 65.67 [2] - The price-to-book ratio (P/B) is 1.3, which is better than the industry average of 3.77, ranking 15th [2] - The return on equity (ROE) is -0.29%, significantly below the industry average of 1.84% [2] Capital Flow - On October 20, 2025, the net inflow of main funds was 770,000 yuan, accounting for 1.6% of the total transaction value [1] - Retail investors contributed a net inflow of 2.6868 million yuan, representing 5.58% of the total transaction value [1] - Over the past five days, the stock has experienced fluctuations in capital flow, with notable net outflows from speculative funds [1]

Core Viewpoint - The stock of Shangrong Medical (002551) has shown a stable price of 4.0 yuan as of October 16, 2025, with a slight increase in main capital inflow, indicating potential interest from institutional investors despite overall negative performance in recent financial results [1][2]. Financial Performance - Shangrong Medical reported a total revenue of 528 million yuan for the first half of 2025, a year-on-year decrease of 16.38% [2] - The company recorded a net profit of -7.76 million yuan, down 155.31% year-on-year, indicating significant financial distress [2] - The second quarter of 2025 saw a single-quarter revenue of 248 million yuan, a decline of 30.12% compared to the same period last year [2] - The company's gross margin stands at 16.47%, significantly lower than the industry average of 51.85% [2] Market Position - Shangrong Medical's total market capitalization is 3.38 billion yuan, which is below the industry average of 11.88 billion yuan, ranking 97 out of 123 in the medical device sector [2] - The company has a price-to-earnings ratio of -217.96, indicating negative earnings, while the industry average is 66.63 [2] - The net asset value is 2.76 billion yuan, compared to the industry average of 3.89 billion yuan, ranking 57 out of 123 [2] Capital Flow Analysis - On October 16, 2025, the main capital inflow was 3.62 million yuan, accounting for 6.18% of the total transaction volume, suggesting some institutional buying interest [1] - Over the past five days, the stock has experienced fluctuations in capital flow, with notable outflows from retail investors [1]

Core Insights - The stock of Shangrong Medical (002551) closed at 4.0 yuan on October 15, 2025, with a 1.78% increase and a trading volume of 165,600 shares, amounting to a total transaction value of 65.91 million yuan [1] Financial Performance - Shangrong Medical reported a total revenue of 528 million yuan for the first half of 2025, representing a year-on-year decline of 16.38% [2] - The net profit attributable to shareholders was -7.76 million yuan, a decrease of 155.31% year-on-year [2] - The company's gross profit margin stood at 16.47%, significantly lower than the industry average of 51.85% [2] - The company had a debt ratio of 21.99% and reported investment income of 7.09 million yuan [2] Market Position - Shangrong Medical's total market capitalization is 3.38 billion yuan, which is below the industry average of 11.88 billion yuan, ranking 97th out of 123 companies in the medical device sector [2] - The company's price-to-earnings ratio (P/E) is -217.96, indicating negative earnings, while the industry average is 67.67 [2] - The return on equity (ROE) for Shangrong Medical is -0.29%, compared to the industry average of 1.8%, ranking 102nd in the sector [2] Capital Flow - On October 15, 2025, the net outflow of main funds was 530,900 yuan, accounting for 0.81% of the total transaction value, while retail investors saw a net inflow of 1.30 million yuan, representing 1.97% of the total transaction value [1]

Core Viewpoint - The stock of Shangrong Medical (002551) has shown a decline in both price and financial performance, indicating potential challenges in the company's operations and market position [1][3]. Financial Performance - As of September 22, 2025, Shangrong Medical's stock closed at 4.01 yuan, down 2.67% with a trading volume of 226,300 hands and a total transaction amount of 90.93 million yuan [1]. - The company reported a total revenue of 528 million yuan for the first half of 2025, a year-on-year decrease of 16.38% [3]. - The net profit attributable to shareholders was -7.76 million yuan, representing a year-on-year decline of 155.31% [3]. - The second quarter of 2025 saw a significant drop in revenue to 248 million yuan, down 30.12% year-on-year, and a net profit of -21.72 million yuan, a staggering decline of 15,273.62% [3]. Market Position - Shangrong Medical's total market capitalization is 3.39 billion yuan, significantly lower than the industry average of 11.91 billion yuan, ranking 97 out of 123 in the medical device industry [3]. - The company's net assets stand at 2.763 billion yuan, compared to the industry average of 3.889 billion yuan, ranking 57 out of 123 [3]. - The company's price-to-earnings ratio is -218.51, while the industry average is 64.67, indicating a poor earnings performance relative to peers [3]. - The gross margin is reported at 16.47%, significantly below the industry average of 51.85%, ranking 119 out of 123 [3]. Capital Flow - On September 22, 2025, the net outflow of main funds was 25.13 million yuan, accounting for 27.63% of the total transaction amount, while retail investors saw a net inflow of 17.61 million yuan, making up 19.37% of the total [1][2]. - Over the past five days, the stock has experienced fluctuating capital flows, with notable net outflows from main funds on several days, indicating a lack of confidence from institutional investors [2].